Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., U.S., No. 17-1229, amicus brief supporting a petition for certiorari, filed 3/30/2018.
The Federal Circuit failed to give effect to a revision of the “on sale” doctrine made by the America Invents Act (AIA) which imposed a “public availability” requirement not only on the fact of an early sale but also on the subject matter of the sale, i.e., the “claimed invention,” according to an AIPLA amicus brief supporting a petition for Supreme Court review.
The revision was intended to bring transparency, objectivity, and predictability to the patent system, consistent with the AIA’s conversion of U.S. patent law from a “first to invent” system to a “first inventor to file.” Although the statutory term “available to the public” may need case-by-case development for different types of inventions, this cannot justify turning a blind eye to the express language of the statute. That language, at a minimum, requires that the “claimed invention”—with all of its claim limitations—be “available to the public.”
The Federal Circuit decision will convert what should be a legal issue in most cases into a fact-intensive issue in many cases, not only jeopardizing the prior investment in inventions claimed in the patent(s)-in-suit, but also increasing the time and expense required for discovery, motion practice, trial, and appellate review.
Upcoming Events
-
2024 Women in IP Law Global Networking Event
April 18, 2024
The annual Global Networking Event connects intellectual property practitioners from around the world for a day of networking, education, and creating meaningful connections. This year’s theme, Cultivating Leaders, is an opportunity for the AIPLA Women in IP Law Committee to help nurture and cultivate future leaders in the profession. -
World IP Day 2024
May 1, 2024 4:00 PM to 7:00 PM
Join AIPLA and partner organizations on May 1 in Washington, DC, for a special three-hour program to celebrate World Intellectual Property Day 2024. This annual international event is an opportunity to learn about the role that intellectual property (IP) rights play in encouraging innovation and creativity. The theme of this year’s celebration is “IP and the SDGs: Building Our Common Future With Innovation and Creativity.” -
2024 Advanced Chemical Patent Practice Institute
May 14 to 15, 2024
This advanced course offers how the chemical/pharma patent practitioners can use fundamentally sound but oft overlooked principles to prepare and prosecute a United States chemical/pharma patent application to withstand both PTAB and district court challenges. The principles taught will greatly help those advanced chemical/pharma patent practitioners involved with prelitigation, portfolio management, litigation, Orange Book listings, Purple Book/BCPIA, regulatory practice, due diligence, health checks, and analysis of third-party patents for validity/patentability, infringement, and enforceability issues, as well as for preparing IPR and/or PGR petitions and defending the patent against them. -
AIPLA 2024 Spring Meeting
May 16 to 18, 2024
Join us as we bring IP professionals together to learn and connect. More information coming soon! The 2024 Spring meeting will take place in downtown Austin, at the Hilton Austin. Leadership Meetings on Wednesday, May 15. Programming scheduled May 16-18.